Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06182358 · ClinicalTrials.gov registry record · Phase 4
Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers
A Phase 4 study of Demodex Blepharitis, sponsored by Tarsus Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 145
- Enrollment target
- 14
- Study locations
NCT06182358 is a Phase 4 study of Demodex Blepharitis that has completed, run by Tarsus Pharmaceuticals. The registered enrollment target is 145 participants. The trial reports 14 study locations across 14 states.
The verdict
NCT06182358, a Phase 4 study of Demodex Blepharitis, has completed, sponsored by Tarsus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 145 participants
- Enrollment target
- 14
- Study locations
Study Summary
To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.
Conditions Studied
Interventions
- DRUG Lotilaner ophthalmic solution, 0.25%
- DRUG Vehicle control
Study Locations (14)
Arizona
- Site - Cave Creek
California
- Site - Long Beach
Colorado
- Vision Institute - Colorado Springs
Florida
- Site - Delray Beach
Indiana
- Site - Indianapolis
Kansas
- Site - Pittsburg
Kentucky
- Site - Louisville
Minnesota
- Site - Edina
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2023-12-27 |
| Est. Completion | 2025-01-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06182358
The ClinicalTrials.gov registry entry for NCT06182358 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tarsus Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Demodex Blepharitis appearing as the primary indexed condition, and to 2 interventions - of which Lotilaner ophthalmic solution, 0.25% is the first listed.
NCT06182358 reports 14 study locations spanning 14 distinct geographic areas - top geographies include Arizona, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06182358 about?
NCT06182358 is a clinical study titled "Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers". To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.
What is the current status of trial NCT06182358?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 145 participants. The study started on 2023-12-27. Estimated completion is 2025-01-27.
What conditions does trial NCT06182358 study?
This clinical trial studies the following conditions: Demodex Blepharitis.
What interventions are being tested in trial NCT06182358?
The interventions under investigation include: Lotilaner ophthalmic solution, 0.25% (DRUG), Vehicle control (DRUG).
Who is sponsoring clinical trial NCT06182358?
This trial is sponsored by Tarsus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06182358 being conducted?
This trial has 14 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Demodex Blepharitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.